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Abstract
Aims: To investigate the prognostic value of coronary dominance for various adverse clinical events follow-
ing the implantation of drug-eluting stents.
Methods and results: We assessed two-year follow-up data of 1,387 patients from the randomised 
TWENTE trial. Based on the origin of the posterior descending coronary artery, coronary circulation was cat-
egorised into left and non-left dominance (i.e., right and balanced). Target vessel-related myocardial infarc-
tion (MI) was defined according to the updated Academic Research Consortium (ARC) definition (2x upper 
reference limit of creatine kinase [CK], confirmed by CK-MB elevation), and periprocedural MI (PMI) as MI 
≤48 hours following PCI. One hundred and thirty-six patients (9.8%) had left and 1,251 (90.2%) non-left 
dominance. Target lesions were more frequently located in dominant arteries (p<0.005). Left dominance was 
associated with more severe calcifications (p=0.006) and more bifurcation lesions (p=0.031). Non-left domi-
nance tended to be less frequent in men (p=0.09). Left coronary dominance was associated with more target 
vessel-related MI (14 [10.3%] vs. 62 [5.0%], p=0.009). Left dominance independently predicted PMI 
(adjusted HR 2.19, 95% CI: 1.15-4.15, p=0.017), while no difference in other clinical endpoints was observed 
between dominance groups.
Conclusions: In the population of the TWENTE trial, we observed a higher incidence of periprocedural 
myocardial infarction in patients who had left coronary dominance.
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Abbreviations
ARC Academic Research Consortium
DES drug-eluting stents
LAD left anterior descending artery
LCX left circumflex artery
MACE major adverse cardiac events
MI myocardial infarction
PCI percutaneous coronary intervention
PDA posterior descending artery
PMI periprocedural myocardial infarction
RCA right coronary artery
STEMI ST-elevation myocardial infarction
TLF target lesion failure
TLR target lesion revascularisation
TVF target vessel failure
TVR target vessel revascularisation
Introduction
Left coronary artery dominance is a variant of the normal coronary 
anatomy, in which the left circumflex artery reaches the crux and 
supplies both posterior descending and posterolateral branches1,2. 
A recent post-mortem analysis showed a decreasing prevalence of 
left dominance with the increase of age, suggesting a worse progno-
sis for subjects with this dominance pattern3. The database of a reg-
istry of patients undergoing cardiac catheterisation for acute 
coronary syndromes has demonstrated higher all-cause mortality in 
patients with left dominance4. In addition, a non-invasive study 
with computed tomography coronary angiography screening of the 
coronary arteries in a heterogeneous group of patients with chest 
pain (with or without coronary artery disease) showed left domi-
nance to be an independent predictor of non-fatal myocardial 
infarction (MI) and all-cause mortality2.
However, there is limited knowledge about the relation between 
coronary dominance patterns and the risk of various adverse clini-
cal events that can occur following percutaneous coronary interven-
tions (PCI) with contemporary drug-eluting stents (DES). The aim 
of this study was to investigate the prognostic value of left domi-
nance in relation to post-PCI outcome – in particular the rate of 
periprocedural MI (PMI), which in current DES studies has the 
highest incidence of all adverse clinical events5-7. We performed the 
analyses in patients in the prospective, randomised TWENTE 
trial5,8, which assessed a population of PCI patients with broad 
inclusion and only few exclusion criteria, treated with second-gen-
eration DES9.
Methods
STUDY POPULATION
The study assessed patients enrolled in the TWENTE trial 
(ClinicalTrials.gov NCT01066650), which has previously been 
described in detail5,8. In brief, TWENTE is an investigator-initiated, 
patient-blinded, randomised non-inferiority study with broad inclu-
sion and limited exclusion criteria in a study population with 
a majority of complex lesions and “off-label” indications for DES 
use. The study was performed between June 2008 and August 2010 
at the Thoraxcentrum Twente, Enschede, The Netherlands. Patients 
with an indication for PCI with DES, who were capable of provid-
ing informed consent, were randomised for treatment with one of 
two types of second-generation DES – Resolute (Medtronic Inc., 
Minneapolis, MN, USA) or XIENCE V (Abbott Vascular, Santa 
Clara, CA, USA). There was no limit for lesion length, reference 
vessel size, and number of target lesions or vessels to be treated. As 
a consequence, in a high proportion of study patients there was 
advanced coronary disease requiring treatment of multiple vessels, 
bifurcation lesions, long lesions, and lesions in small vessels5. 
A total of 52% of patients presented with an acute coronary syn-
drome but, as a very recent ST-elevation myocardial infarction 
(STEMI) was the most important exclusion criterion, patients 
requiring primary PCI were not enrolled. The TWENTE trial has 
demonstrated a similar clinical outcome for both DES5. The study 
was approved by the institutional ethics committee and complied 
with the Declaration of Helsinki. All patients provided written 
informed consent. The study population of the present analysis con-
sisted of all TWENTE patients except four patients who withdrew 
their consent during follow-up.
ANGIOGRAPHIC ASSESSMENT OF CORONARY ARTERY 
DOMINANCE
Coronary dominance was classified into left and non-left by two 
experienced analysts who inspected the coronary angiography of 
all TWENTE patients. A coronary artery system was classified as 
right dominant when the PDA originated from the right coronary 
artery (RCA), while left dominance was defined when the PDA 
originated from the left circumflex artery (LCX). A balanced 
dominant coronary system was categorised when the PDA rose 
from the RCA in combination with a large posterolateral branch 
originating from the LCX reaching near the posterior interven-
tricular groove2. Right and balanced were referred to as non-left 
dominance. Any potential disagreement between analysts was 
resolved by jointly inspecting all angiographic runs available in 
order to achieve consensus.
QUANTITATIVE CORONARY ANGIOGRAPHY
Quantitative coronary angiographic analyses were performed 
offline with the use of edge-detection software (QAngio XA ver-
sion 7.1; Medis, Leiden, The Netherlands) by angiographic analysts 
from the Thoraxcentrum Twente5.
FOLLOW-UP AND DEFINITION OF CLINICAL ENDPOINTS
Details of the clinical follow-up have been reported previously5,8. In 
brief, in the TWENTE trial follow-up data were obtained during 
two-year follow-up after the index procedure. For any events trig-
gered, all available relevant clinical information was gathered. 
Clinical event adjudication (follow-up information was available 
for all patients) was performed by a core laboratory and an external 
independent research organisation (Cardialysis, Rotterdam, The 
Netherlands). Clinical endpoints were classified according to the 
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Academic Research Consortium (ARC) definitions10,11. Cardiac 
death was defined as any death due to proximate cardiac cause (e.g., 
MI, low-output failure, fatal arrhythmia). MI was defined by any 
creatine kinase concentration of more than double the upper limit of 
normal with elevated values of a confirmatory cardiac biomarker 
(creatine kinase myocardial band fraction or troponin), based on the 
updated ARC definition of MI. Periprocedural MI (PMI) was 
defined as MI within 48 hours after PCI10,11. Further classification 
of MI and MI location was based on laboratory information, elec-
trocardiogram, and/or clinical data. Laboratory information 
included determination of creatine kinase before PCI and cardiac 
markers six to 18 hours after PCI, with subsequent serial measure-
ments in case of relevant biomarker elevation or complaints (97% 
of the cases had at least one blood sampling performed between 12 
and 18 hours after PCI). Stent thrombosis was defined according to 
ARC as definite or probable.
The composite endpoint of target vessel failure (TVF) was 
defined as cardiac death, target vessel-related MI, or clinically 
driven target vessel revascularisation (TVR). Target lesion failure 
(TLF) was defined as the composite of cardiac death, target vessel-
related MI, and clinically indicated target lesion revascularisation 
(TLR); major adverse cardiac events as the composite of all-cause 
death, any MI, emergent coronary artery bypass surgery, or clini-
cally indicated TLR; and a patient-oriented composite endpoint as 
the composite of all-cause mortality, any MI, and any repeat (target 
and non-target vessel) revascularisation5.
STATISTICAL ANALYSIS
Categorical data were presented as frequencies and percentages 
whereas continuous variables were expressed as mean±standard 
deviation (SD). To assess potential differences in the prevalence of 
dominance patterns between younger and older patients, age was 
categorised using the mean of the total population as the cut-off 
value. The baseline characteristics were compared using the chi-
square test or Fisher’s exact test for categorical variables and one-
way analysis of variance (ANOVA) for continuous variables 
including age, BMI, minimum reference diameter and total stent 
length, as the data were distributed normally. The Kruskal-Wallis 
test (non-parametric data) was used to compare the total number of 
stents placed between dominance patterns, and results presented as 
median and interquartile range (IQR). Univariate and Cox regres-
sion analysis was performed to assess coronary dominance as an 
independent predictor with respect to the predefined endpoints. 
Potential confounding was identified if p-values were <0.10 at uni-
variate analysis of the relations between tested parameter and both 
dominance and predefined clinical endpoints. A multivariate Cox 
regression analysis was then performed to adjust for potential con-
founders. The time to MI was assessed according to the Kaplan-
Meier method, in which the log-rank test was applied to compare 
the coronary dominance patterns. Analyses were performed using 
SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Unless otherwise speci-
fied, confidence intervals and p-values were two-sided. A p-value 
<0.05 was considered statistically significant.
Results
PATIENT CHARACTERISTICS
A total of 1,387 patients were analysed, of whom 136 (9.8%) had 
left dominance and 1,251 (90.2%) non-left dominance, consisting 
of 1,077 (77.6%) right and 174 (12.5%) balanced dominance. In all 
1,387 patients, follow-up data were available. Baseline characteris-
tics are shown in Table 1. Male gender tended to be more frequent 
in the left than in the non-left dominance group (78.7% vs. 71.8%, 
respectively; p=0.087). There was no difference in the prevalence 
of dominance patterns between patients aged ≤64 and older 
(p=0.79). Patients with left dominance tended less often to have 
a previous PCI (p=0.11).
ANGIOGRAPHIC AND PROCEDURAL CHARACTERISTICS
Angiographic analysis revealed that target lesions were more fre-
quently located in the dominant artery (Table 2): left and non-left 
dominance were present in 64.0% vs. 50.8% if target lesions were 
located in the left anterior descending artery (LAD; p=0.004), 
50.7% vs. 29.4% if target lesions were located in the LCX 
(p<0.001), and 6.6% vs. 39.4% if target lesions were located in the 
RCA (p<0.001).
The ACC/AHA lesion types did not differ in complexity between 
dominance groups (p=0.6). Left dominance was associated with 
more severe lesion calcification (p=0.006), more bifurcation lesions 
(p=0.031), and showed a trend towards more de novo lesions 
(p=0.079). Between dominance groups, there was no significant 
difference in minimum reference vessel size, the number of lesions 
treated, and other procedural details.
ADVERSE CLINICAL EVENTS DURING TWO-YEAR FOLLOW-UP
Left dominance was associated with a higher incidence of target 
vessel MI (p=0.009) (Table 3), in particular non-Q-wave MI 
(p=0.001) and PMI (p=0.004). For all other adverse cardiac events 
and composite endpoints, there was no significant difference 
between dominance groups. Definite or probable stent thrombosis 
was non-significantly more frequent in patients with left dominance 
than in non-left dominance (2.2% vs. 1.2%, respectively).
MULTIVARIATE ANALYSIS OF CORONARY DOMINANCE AND 
MYOCARDIAL INFARCTION
Severe lesion calcification and at least one bifurcated lesion were 
considered as potential confounders and were therefore included as 
covariates in a multivariate model. Using the largest group with 
non-left dominance as a reference, left coronary dominance was 
shown to be a significant independent predictor of target vessel MI 
(adjusted HR 1.88, 95% CI: 1.05-3.37, p=0.034) - mainly non-Q-
wave MI (adjusted HR 2.35, 95% CI: 1.26-4.36, p=0.007) and PMI 
(adjusted HR 2.19, 95% CI: 1.15-4.15, p=0.017). In addition, 
severe lesion calcification and at least one bifurcated lesion were 
independent predictors for target vessel MI (adjusted HR 2.16, 95% 
CI: 1.35-3.46, p=0.001, adjusted HR 1.60, 95% CI: 1.00-2.55, 
p=0.048, respectively) and for non-Q-wave MI (adjusted HR 1.81, 
95% CI: 1.05-3.14, p=0.034, adjusted HR 2.00, 95% CI: 1.19-3.56, 
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p=0.009, respectively). For PMI, severe lesion calcification tended 
to predict PMI (adjusted HR 1.75, 95% CI: 0.99-3.07, p=0.051) and 
at least one bifurcated lesion was an independent predictor (adjusted 
HR 2.13, 95% CI: 1.26-3.59, p=0.005). Kaplan-Meier MI-free sur-
vival analysis stratified for the dominance groups demonstrated 
a higher incidence of MI in patients with left dominance (p=0.009) 
(Figure 1). The MI occurred most frequently as PMI – that is, 
within the first two days, after which both survival curves showed 
hardly any change.
Discussion
Within the 1,387 patients of the prospective randomised TWENTE 
trial, left coronary dominance was an independent predictor of PMI 
following the implantation of contemporary second-generation 
DES and was associated with a higher MI rate at two-year follow-
up. The relation between left coronary dominance and both MI and 
PMI remained after correcting for confounders, including severe 
lesion calcification and at least one bifurcated lesion. Despite sig-
nificant differences in PMI and MI rates at two-year follow-up, no 
Table 1. Patient characteristics in left and non-left coronary dominance.
Total population 
(n=1,387)
Left 
(n=136)
Non-left 
(n=1,251)
p-value
Age All patients (years) 64.3 (10.6) 64.6 (10.7) 64.2 (10.5) 0.685
Equal to or younger than 64 years 688 (49.6) 66 (48.5) 622 (49.7) 0.792
Older than 64 years 699 (50.4) 70 (51.5) 629 (50.3)
Gender (male) (%) 1,005 (72.5) 107 (78.7) 898 (71.8) 0.087
Clinical risk factor Diabetes mellitus (any) 299 (21.6) 29 (21.3) 270 (21.6) 0.944
Hypercholesterolaemia 801/1,353 (59.2) 78/132 (59.1) 723/1,221 (59.2) 0.978
Arterial hypertension 771 (55.6) 75 (55.1) 696 (55.6) 0.913
Family history of CAD 737 (53.1) 65 (47.8) 672 (53.7) 0.189
Current smoking 340 (24.5) 33 (24.3) 307 (24.5) 0.943
BMI (kg/m3) 27.7±4.0 (1,186) 28.1±3.8 (118) 27.7±4.0 (1,068) 0.299
Known vascular 
disease (%)
Previous MI (any) 450 (32.4) 45 (33.1) 405 (32.4) 0.866
Previous PCI 287 (20.7) 21 (15.4) 266 (21.3) 0.111
Previous CABG 148 (10.7) 14 (10.3) 134 (10.7) 0.881
Previous heart valve surgery 4/1,368 (0.3) 0/135 (0.0) 4/1,233 (0.3) 1.000
Previous stroke 43 (3.1) 6 (4.4) 37 (3.0) 0.304
Previous TIA 70 (5.0) 8 (5.9) 62 (5.0) 0.639
Clinical indication Stable angina pectoris 672 (48.4) 73 (53.7) 599 (47.9) 0.436
Unstable angina pectoris 324 (23.4) 29 (21.3) 295 (23.6)
Non-ST-elevation MI 391 (28.2) 34 (25.0) 357 (28.5)
Medication usage Acetylsalicylic acid 1,376 (99.2) 135 (99.3) 1,241 (99.2) 1.000
Clopidogrel 1,387 (100) 136 (100) 1,251 (100)
Statins 1,191 (85.9) 111 (81.6) 1,080 (86.3) 0.134
Beta-blocker 1,145 (82.6) 116 (85.3) 1,029 (82.3) 0.375
ACE inhibitor 394 (28.4) 39 (28.7) 355 (28.4) 0.941
Left ventricular ejection fraction <30%* 32/1,048 (3.1) 5/95 (5.3) 27/953 (2.8) 0.202
Values are n (%) or mean±SD. *Left ventricular ejection fraction assessed with ultrasound, magnetic resonance imaging or left ventricular angiography. 
BMI: body mass index; CABG: coronary artery bypass grafting; CAD: coronary artery disease; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; TIA: transient ischaemic attack
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Figure 1. MI-free survival in patients with non-left and left coronary 
dominance (2-year follow-up).
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Table 2. Baseline lesion and angiographic characteristics in patients with left and non-left coronary dominance.
Total 
(n=1,387)
Left 
(n=136)
Non-left 
(n=1,251)
p-value
Target lesion coronary 
artery
Left main stem 52 (3.7) 7 (5.1) 45 (3.6) 0.366
Left anterior descending artery (LAD) 723 (52.1) 87 (64.0) 636 (50.8) 0.004
Left circumflex artery (LCX) 437 (31.5) 69 (50.7) 368 (29.4) <0.001
Right coronary artery (RCA) 502 (36.2) 9 (6.6) 493 (39.4) <0.001
Bypass graft 41 (3.0) 2 (1.5) 39 (3.1) 0.423
ACC/AHA lesion class A 91 (6.6) 12 (8.8) 79 (6.3) 0.591
B1 294 (21.2) 27 (19.9) 267 (21.3)
B2 428 (30.9) 45 (33.1) 383 (30.6)
C 574 (41.4) 52 (38.2) 522 (41.7)
Type of lesions De novo lesions only* 1,284 (92.6) 131 (96.3) 1,153 (92.2) 0.079
At least one chronic total occlusion 95 (6.8) 9 (6.6) 86 (6.9) 0.910
At least one in-stent restenosis 68 (4.9) 3 (2.2) 65 (5.2) 0.125
At least one bifurcation lesion 362 (26.1) 46 (33.8) 316 (25.3) 0.031
At least one aorto-ostial lesion 152 (11.0) 8 (5.9) 144 (11.5) 0.046
At least one severe calcification 274 (19.8) 39 (28.7) 235 (18.8) 0.006
At least one thrombus present# 61 (4.4) 4 (2.9) 57 (4.6) 0.510
At least one total occlusion 184 (13.3) 16 (11.8) 168 (13.4) 0.587
Total number of 
lesions treated/patient
1 lesion treated 856 (61.7) 84 (61.8) 772 (61.7) 0.913
2 lesions treated 391 (28.2) 37 (27.2) 354 (28.3)
3 or more lesions treated 140 (10.1) 15 (11.0) 125 (10.0)
Multivessel treatment 334 (24.1) 34 (25.0) 300 (24.0) 0.792
PCI-related 
characteristics
Minimum reference diameter (mm) 2.6±0.6 2.5±0.6 2.6±0.6 0.198
Total number of stents 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 0.591
Total stent length (mm) 40.98±26.9 39.2±24.1 41.4±27.1 0.419
At least one direct stenting 662 (47.7) 62 (45.6) 517 (48.0) 0.868
At least one stent post-dilation 1,218 (87.8) 121 (89.0) 948 (88.0) 0.665
Maximal inflation pressure (atm) 15.9±2.6 15.9±2.8 15.9±2.6 0.898
Values are n (%), mean±SD or median (IQR). *Including chronic total occlusion but not grafts and in-stent restenosis. #Thrombus triggering use of 
thrombus aspiration catheters. ACC: American College of Cardiology; AHA; American Heart Association
difference in other clinical endpoints was observed between domi-
nance groups. While the present study adds novel information on 
the relation between coronary anatomy and clinical outcome fol-
lowing PCI, the limited power of the analysis requires that the find-
ings of this study should be considered as hypothesis-generating.
PERIPROCEDURAL MYOCARDIAL INFARCTION
This study demonstrated that left dominance is associated with 
a 2.2-times higher risk of PMI. The relation between anatomical 
features such as the coronary distribution pattern and PMI had not 
been assessed until now. In DES trials, the MI rate is a component 
of several combined clinical endpoints; the PMI rate represents the 
vast majority of the MI rate which is an endpoint in both stent trials 
and pathophysiological studies12-15. The mechanism underlying the 
increased PMI risk in left coronary dominance is still unclear. 
Previous studies have demonstrated that complex plaque morphol-
ogies and greater atheroma volumes bear a greater risk of signifi-
cant plaque (micro)embolisation which can lead to microvascular 
injury16-20. Furthermore, PCI-related (stent-induced) closure of epi-
cardial arteries may lead to blood flow reduction or occlusion in 
side branches with subsequent myocardial injury16. Both microem-
bolisation and stent-induced closure of very small side branches 
may not be visible on the angiogram but can lead to cardiac marker 
release and PMI.
CLINICAL OUTCOME
A few registries and studies have shown relations between left domi-
nance and inferior clinical outcome2-4, but the patient populations of 
these studies differed significantly from that of the TWENTE trial5. 
A recently published post-mortem angiography study showed that 
the prevalence of left and balanced dominance decreased with 
increasing age3, while we found no relation between age and domi-
nance pattern in the population of TWENTE trial patients, who were 
on average at a younger age (being normally distributed) than the 
population of the aforementioned post-mortem study that also 
comprised a wider age range (with non-Gaussian distribution). 
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In a heterogeneous group of patients with chest pain, computed 
tomography coronary angiographic screening revealed left domi-
nance to be an independent predictor of non-fatal MI and all-cause 
mortality2. In addition, in a registry of patients with acute coronary 
syndromes, left dominance was associated with higher all-cause 
mortality4.
Our present study in a population of PCI patients with broad 
inclusion and only few exclusion criteria, consisting almost equally 
of patients with acute coronary syndromes and stable angina5,9, adds 
further information on the prognostic impact of left coronary domi-
nance with regard to various aspects of clinical outcome following 
PCI. Although we did not observe an inferior outcome in terms of 
higher mortality, treatment failure, or major adverse cardiac events, 
we found an independent association between left dominance and 
PMI which, in the presence of major cardiac marker release, may be 
related to increased mortality16,21-24. Furthermore, in patients with 
left dominance we observed more bifurcated and severely calcified 
coronary lesions, lesions with characteristics that are known to be 
associated with inferior clinical outcome25. While our data may not 
have direct clinical implications, our findings suggest that further 
research may be warranted to clarify the role of coronary domi-
nance. Left coronary dominance in the presence of left main disease 
and a proximal LAD stenosis may sometimes lead to surgical revas-
cularisation or, if PCI is performed, may trigger a more aggressive 
pharmacological antiplatelet and/or anticoagulation therapy, as the 
occlusion of a dominant CX artery may induce serious complica-
tions. This impact of a dominant circumflex coronary artery on PCI 
procedural risk is also reflected in the SYNTAX score26,27.
Limitations
The present study is a non-pre-specified post hoc analysis of the 
TWENTE trial with two-year clinical follow-up. Nevertheless, any pro-
longation of follow-up would have had no effect on the difference in 
PMI between dominance groups (PMI may only occur during the first 
48 hours after PCI), which was the main finding of this study. In addi-
tion, none of the other clinical outcome parameters (i.e., other than MI 
and PMI) showed a trend towards significant difference between coro-
nary dominance groups. While the adjudication of MI was performed 
according to the ARC definitions, we did not stratify events for different 
levels of CK-MB elevation (e.g., >5x or >10x the upper reference limit 
of CK-MB). In future assessments of this issue, it may be valuable to 
stratify the CK-MB value to certain levels in order to define the severity 
of MI better. In addition, we cannot completely exclude that during fol-
low-up a subclinical MI might have been missed, especially if it did not 
lead to hospitalisation, revascularisation by PCI or CABG, and/or if 
ECG changes were not recognisable. Because of the limited power of 
the present post hoc analysis, no definite conclusion can be drawn and 
findings should be considered hypothesis-generating. Nevertheless, the 
current findings add novel information on the relation between coronary 
anatomy and clinical outcome following PCI.
Table 3. 2-year clinical outcome in patients with left and non-left coronary dominance.
Total 
(n=1,387)
Left 
(n=136)
Non-left 
(n=1,251)
p-value
Death Any cause 62 (4.5) 8 (5.9) 54 (4.3) 0.401
Cardiac cause 30 (2.2) 4 (2.9) 26 (2.1) 0.528
Myocardial infarction Any 79 (5.7) 14 (10.3) 65 (5.2) 0.015
Target-vessel 76 (5.5) 14 (10.3) 62 (5.0) 0.009
Q-wave 17 (1.2) 1 (0.7) 16 (1.3) 1.000
Non-Q-wave 59 (4.3) 13 (9.6) 46 (3.7) 0.001
Periprocedural MI 57 (4.1) 12 (8.8) 45 (3.6) 0.004
Major adverse cardiac events* 172 (12.4) 22 (16.2) 150 (12.0) 0.160
Patient-oriented composite endpoint# 232 (16.7) 28 (20.6) 204 (16.3) 0.204
Clinically indicated 
TVR
Any 74 (5.3) 5 (6.8) 69 (5.5) 0.365
Percutaneous 60 (4.3) 3 (2.2) 57 (4.6) 0.201
Surgical 16 (1.2) 2 (1.5) 14 (1.1) 0.665
Clinically indicated 
TLR
Any 52 (3.7) 3 (2.2) 49 (3.9) 0.318
Percutaneous 41 (3.0) 2 (1.5) 39 (3.1) 0.423
Surgical 13 (0.9) 1 (0.7) 12 (1.0) 1.000
Target lesion failure 141 (10.2) 18 (13.2) 123 (9.8) 0.212
Target vessel failure 155 (11.2) 19 (14.0) 136 (10.9) 0.276
Stent thrombosis (definite or probable) 18 (1.3) 3 (2.2) 15 (1.2) 0.410
Values are n (%). *Major adverse cardiac events are a composite of all-cause death, any myocardial infarction (MI), emergent coronary artery bypass 
surgery, or clinically indicated target lesion revascularisation (TLR). #Patient-oriented composite endpoint is a composite of endpoint af all-cause death, 
any MI, or any revascularisation. TVR: target vessel revascularisation
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Conclusion
In the population of the TWENTE trial, we observed a higher inci-
dence of periprocedural myocardial infarction in patients who had 
left coronary dominance.
Impact on daily practice
Revascularisation of a significant lesion in a left-dominant coro-
nary system may be associated with an increased risk of peripro-
cedural myocardial infarction. In such lesions, additional 
measures to prevent this adverse event may be considered (e.g., 
more aggressive pharmacological therapy). In the presence of 
significant left main and proximal LAD disease with unfavoura-
ble anatomies, left coronary dominance may sometimes suggest 
serious consideration of surgical coronary revascularisation.
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